These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34632486)

  • 1. Prognostic influence of a ground-glass opacity component in hypermetabolic lung adenocarcinoma.
    Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
    Eur J Cardiothorac Surg; 2022 Jan; 61(2):249-256. PubMed ID: 34632486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma.
    Hattori A; Hirayama S; Matsunaga T; Hayashi T; Takamochi K; Oh S; Suzuki K
    J Thorac Oncol; 2019 Feb; 14(2):265-275. PubMed ID: 30368010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncological characteristics of epidermal growth factor receptor-mutated clinical stage IA lung adenocarcinoma with radiologically pure-solid appearance.
    Hattori A; Matsunaga T; Fukui M; Tomita H; Takamochi K; Suzuki K
    J Thorac Cardiovasc Surg; 2024 Sep; 168(3):685-696.e2. PubMed ID: 37995863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of tumour spread through air space in radiological subsolid and pure solid lung adenocarcinoma.
    Zhong Y; Xu Y; Deng J; Wang T; Sun X; Chen D; Wu C; Hou L; Xie H; She Y; Xie D; Chen C
    Eur J Cardiothorac Surg; 2021 Apr; 59(3):624-632. PubMed ID: 33188689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a Ground-glass Opacity Component on c-Stage IA Lung Adenocarcinoma.
    Li M; Xi J; Sui Q; Kuroda H; Hamanaka K; Bongiolatti S; Hong G; Zhan C; Feng M; Wang Q; Tan L
    Semin Thorac Cardiovasc Surg; 2023 Winter; 35(4):783-795. PubMed ID: 35907612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of Very Small Ground-Glass Opacity Component in Stage IA Solid Predominant Non-small Cell Lung Cancer.
    Hattori A; Matsunaga T; Fukui M; Suzuki K; Takamochi K; Suzuki K
    Semin Thorac Cardiovasc Surg; 2024 Summer; 36(2):251-260. PubMed ID: 36180013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity.
    Li M; Xi J; Zhang H; Jin X; Zhang J; Feng M; Zhan C; Wang Q
    Ann Thorac Cardiovasc Surg; 2022 Oct; 28(5):320-328. PubMed ID: 35644565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minor (≤ 10%) Ground-Glass Opacity Component in Clinical Stage I Non-Small Cell Lung Cancer: Associations With Pathologic Characteristics and Clinical Outcomes.
    Li M; Wang J; Bao X; Wang F; Zhou F; Song N; Wan Z; Li W; Zhang L
    AJR Am J Roentgenol; 2024 Aug; 223(2):e2431283. PubMed ID: 38809121
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic Classification of Multiple Primary Lung Cancers Based on a Ground-Glass Opacity Component.
    Hattori A; Takamochi K; Oh S; Suzuki K
    Ann Thorac Surg; 2020 Feb; 109(2):420-427. PubMed ID: 31593656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the prognostic implication of ground-glass opacity on CT according to pathological nodal status in lung cancers treated with lobectomy or pneumonectomy.
    Park S; Lee SM; Choe J; Choi S; Kim S; Do KH; Seo JB
    Eur Radiol; 2022 Jul; 32(7):4405-4413. PubMed ID: 35141781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of lymphovascular invasion for stage I lung adenocarcinoma based on the presence of ground-glass opacity.
    Choe J; Lee SM; Park S; Choi S; Do KH; Seo JB
    Eur Radiol; 2024 Sep; ():. PubMed ID: 39285027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resected lung adenocarcinoma with lymph node metastasis: is ground glass opacity component a prognostic factor?
    Deng C; Jiang C; Ma X; Fu F; Wang S; Li Y; Zhang Y; Chen H
    Transl Lung Cancer Res; 2024 Jul; 13(7):1609-1619. PubMed ID: 39118885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
    Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
    Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of a ground glass opacity component in the clinical T classification of non-small cell lung cancer.
    Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Dec; 154(6):2102-2110.e1. PubMed ID: 28947198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of Even a Small Ground-Glass Component in Lung Adenocarcinoma Predicts Better Survival.
    Berry MF; Gao R; Kunder CA; Backhus L; Khuong A; Kadoch M; Leung A; Shrager J
    Clin Lung Cancer; 2018 Jan; 19(1):e47-e51. PubMed ID: 28743420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer.
    Kamigaichi A; Tsutani Y; Mimae T; Miyata Y; Shimada Y; Ito H; Nakayama H; Ikeda N; Okada M
    Eur J Cardiothorac Surg; 2022 Aug; 62(3):. PubMed ID: 35293580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma?
    Nakamura S; Fukui T; Kawaguchi K; Fukumoto K; Hirakawa A; Yokoi K
    Lung Cancer; 2015 Jul; 89(1):38-42. PubMed ID: 25963638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the ground-glass opacity ratio in resected lung adenocarcinoma.
    Huang TW; Lin KH; Huang HK; Chen YI; Ko KH; Chang CK; Hsu HH; Chang H; Lee SC
    Eur J Cardiothorac Surg; 2018 Aug; 54(2):229-234. PubMed ID: 29471517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    Chest; 2014 Jan; 145(1):66-71. PubMed ID: 24551879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence Patterns and Patient Outcomes in Resected Lung Adenocarcinoma Differ according to Ground-Glass Opacity at CT.
    Park S; Lee SM; Choe J; Choi S; Do KH; Seo JB
    Radiology; 2023 May; 307(3):e222422. PubMed ID: 36943079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.